The purpose of this first-in-human study, CTMX-2051-101, is to characterize the safety,
tolerability, and antitumor activity of CX-2051 in adult participants with advanced solid
tumors.
Additional locations may be listed on ClinicalTrials.gov for NCT06265688.
Locations matching your search criteria
United States
Massachusetts
Boston
Dana-Farber Cancer InstituteStatus: Active
Name Not Available
The study is comprised of 2 parts. Part 1 involves CX-2051 dose escalation to identify
the maximum tolerated dose (MTD) of CX-2051. Part 2 (dose expansion) will further assess
safety and tolerability as well as preliminarily assess antitumor activity of CX-2051 in
indication-specific expansion cohorts.
Lead OrganizationCytomX Therapeutics
Principal InvestigatorMonika Vainorius